Phase 4 N=28 Intraoperative Floppy Iris Syndrome
Cataract · Floppy Iris Syndrome
Primary: Corneal Endothelial Cell Loss — 9.85; -3.68 Percent change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=26 Pupil Dilation for Treatment of IFIS
Intraoperative Floppy Iris Syndrome
Primary: Pupil Dilation Sized of the Treated Eye Compared to the Non-treated Eye — 6.76; 7.17 millimeters
N/A N=63 Intraoperative Ocular Pressure in Lumbar Spine Fusion Patients
Raised Ocular Pressure
Primary: Change in Intraoperative Ocular Pressure in Lumbar Spine Fusion Patients Head Raised 10 Degrees or Kept in Neutral Position — 9.26; 13.79 mm Hg
Phase 3 N=405 Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification
Intraocular Lens Replacement
Primary: Mean Area-under-the-Curve (AUC) Analysis of Change From Baseline in Pupil Diameter (mm) During Surgery — 0.1; -0.5 mm — p=<0.0001
Phase 3 N=416 Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification
Intraocular Lens Replacement
Primary: Mean Area Under the Curve Analysis of Change-from-Baseline in Pupil Diameter (mm) During Surgery — 0.1; -0.5 mm — p=0.0001
N/A N=67 The Impacts of Surgical Visibility Through Deep Neuromuscular Blockade on Intraocular Pressure in Patients Undergoing Robot-Assisted Laparoscopic Radical Prostatectomy
Robot-Assisted Laparoscopic Radical Prostatectomy
Primary: Maximum Intraocular Pressure During RALRP Under Deep Neuromuscular Blockade — 23.3; 19.8 mmHg
Phase 4 N=94 No Drop Post-Op Cataract Surgery
Cataract
Primary: Best Corrected Visual Acuity (BCVA) (Pre-op) — .28 LogMar
N/A N=15 Intra-surgical Evaluation of CATS Tonometer Prism and Abbott Medical Optics Versus Alcon Phacoemulsification Machines
Cataract Surgery
Primary: Number of Eyes With Stable IOP — 16; 14 Eyes
N/A N=229 Toric Intraocular Lens Following Cataract Surgery
Cataract · Astigmatism
Primary: Percent Reduction in Absolute Cylinder — 84.975; 46.498 percentage of intended cylinder reduct
N/A N=37 Corneal Incisions With the IntraLase iFS Femtosecond Laser System
Cataract
Primary: Demonstration That the Femtosecond Laser Consistently Produces Desired Incisions. — 2.75; 2.74 mm
N/A N=390 Femtosecond Laser Assisted Cataract Surgery in Intumescent Cataracts
Intumescent Cataract
Primary: Percentage of Capsular Tears (Anterior or Posterior) During Surgery — 5.3; 5.3 percentage of capsular tears
N/A N=66 Physiologic Phacofluidics: Ghost Protocol
Cataract
Primary: Change in Early Post Operative Central Corneal Thickness — 623.9; 650.2 microns
N/A N=10 Intraocular Pressure During Abdominal Aortic Aneurysm (AAA) Repair
Problem With Vision Blindness · Intraocular Pressure · Ischemic Optic Neuropathy
Primary: Right Intraocular Pressure During Various Event Intervals in Open Abdominal Aortic Aneurysm Surgery. — 16.9; 13.8; 14.6; 13.5 mm Hg — p=<0.001
N/A N=3,785 Posterior Capsule Opacification Following Cataract Surgery With Implantation of the MICS IOL L313
Posterior Capsule Opacification
Primary: Percentage of Eyes With Posterior Capsule Opacification Following Implantation of IOL 313 up to 8 Years — 7.9; 4.7; 17.1; 8.2 percentage of eyes
Phase 2 N=172 Efficacy and Safety of IBI-10090 in Ocular Surgery Patients
Inflammation Associated With Cataract Surgery
Primary: Anterior Chamber Cell Count at Day 8 Post-Treatment — 50; 51.8; 60.3 percentage of patients with ACC clearing
N/A N=109 Clinical Investigation of Corneal Incision Size After Intraocular Lens (IOL) Implantation
Cataracts
Primary: Mean Corneal Incision Size After IOL Implantation (UltraSert, iTec, and iSert) — 2.35; 2.47; 2.54 mm
Phase 4 N=100 Clinical Investigation of the Bi Flex M Multifocal IOL
Cataract
Primary: Long Term Monocular Visual Acuity (VA) — 0.192; 0.205; 0.614; 0.319 LogMAR
N/A N=72 Clinical Evaluation of Morcher Artificial Iris Diaphragms
Aniridia · Iris; Deformity
Primary: Change in Light and Glare Sensitivity as Determined by a Clinical Glare Test (Primary Efficacy Measure) — 51; 12; 1 Participants
N/A N=37 Evaluation of Sodium Fluorescein Use During Intraoperative Cystoscopy After Total Laparoscopic Hysterectomy
Ureteral Injury
Primary: Quality of Ureteral Efflux Coloration With Sodium Fluorescein Collected With Dedicated Questionnaire — 23; 4; 1; 1 Participants
N/A N=209 Study of OMNI System in OAG (GEMINI)
Open Angle Glaucoma
Primary: Change in Mean Unmedicated Diurnal IOP — 7.98 mm Hg
N/A N=32 Phacoemulsification Versus Phacoemulsification With Micro-bypass Stent
Primary Angle-Closure Glaucoma · Primary Angle Closure Without Glaucoma Damage
Primary: Change in Intraocular Pressure Between Baseline and 1 Year — 15; 14.7 mmHg
Phase 3 N=78 A Randomized Study in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction With or Without Lens Replacement
Unilateral Cataract Extraction · Congenital Cataract
Primary: Intraoperative Pupil Diameter — 0.14; 0.20 millimeters*minutes
N/A N=50 Efficacy of Fascia Iliaca Block Versus Intraoperative Nerve Infiltration During Anterior Hip Replacement Surgery
Pain, Postoperative
Primary: Postoperative Pain During PACU Admission — 40; 36 units on a scale
Phase 3 N=151 Prevention of Post-operative Urinary Retention
Urinary Retention · Urinary Tract Infections
Primary: Need for Any Intermittent Catheterization Postoperatively as a Binary Outcome — 18; 22 Participants
Phase 4 N=20 Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema
Macular Edema, Cystoid · Vision Disorders · Diabetic Macular Edema
Primary: Change in the Central Macular Thickness — 85.67; -18.22 Microns
Phase 2 N=75 An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product
Primary Open-Angle Glaucoma · Ocular Hypertension
Primary: Percentage of Participants With Ocular and Non-ocular Adverse Events (AE) by Severity — 53.3; 14.7; 1.3; 12.0 percentage of participants
Phase 4 N=76 Visual Function After Implantation of Bilateral AcrySoft ReSTOR Aspheric IOL
Cataract
Primary: Visual Acuity — 0.54; 0.06; 0.03; 0.04 logMAR
N/A N=2,280 Post Approval Study of the AcrySof® IQ ReSTOR® Toric IOLs
Aphakia · Presbyopia · Astigmatism
Primary: Rate of Eyes With Post-Surgical Intraocular Inflammation - By Eye - Cohort 2 — 5.6; 4.5 event rate per 1000 implants
N/A N=32 Clinical Investigation of an AcrySof IQ PanOptix Toric Intraocular Lens
Aphakia · Corneal Astigmatism
Primary: Percentage of Eyes With ≤ 0.25 Diopter (D) Absolute Refractive Cylinder at Visit 3/3A (Day 30-60) — 90.2 percentage of eyes — p=<0.0001
Phase 3 N=26 Utilization and Safety of the Mk II Inserter and the Safety of the FAI Insert in Non-Infectious Uveitis
Non-Infectious Uveitis
Primary: The Utilization of the Mk II Inserter From the Day of Treatment Through 7 Days Following Treatment. — 10; 3; 3; 2 Eyes